ATE495197T1 - Chimäre konstrukte zwischen auf krebs zielenden peptiden und zellpenetrierenden peptiden gekoppelt an antikrebsmittel und/oder diagnostische mittel - Google Patents

Chimäre konstrukte zwischen auf krebs zielenden peptiden und zellpenetrierenden peptiden gekoppelt an antikrebsmittel und/oder diagnostische mittel

Info

Publication number
ATE495197T1
ATE495197T1 AT07716076T AT07716076T ATE495197T1 AT E495197 T1 ATE495197 T1 AT E495197T1 AT 07716076 T AT07716076 T AT 07716076T AT 07716076 T AT07716076 T AT 07716076T AT E495197 T1 ATE495197 T1 AT E495197T1
Authority
AT
Austria
Prior art keywords
cell
seq
peptides
cancer
targing
Prior art date
Application number
AT07716076T
Other languages
English (en)
Inventor
Uelo Langel
Helena Myrberg
Maarja Maee
Erkki Ruoslahti
Lianglin Zhang
Original Assignee
Cepep Iii Ab
Burnham Inst Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cepep Iii Ab, Burnham Inst Medical Research filed Critical Cepep Iii Ab
Application granted granted Critical
Publication of ATE495197T1 publication Critical patent/ATE495197T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/005Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056Peptides, proteins, polyamino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/0019Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043Fluorescein, used in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT07716076T 2006-03-20 2007-03-20 Chimäre konstrukte zwischen auf krebs zielenden peptiden und zellpenetrierenden peptiden gekoppelt an antikrebsmittel und/oder diagnostische mittel ATE495197T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78339606P 2006-03-20 2006-03-20
PCT/SE2007/000268 WO2007108749A1 (en) 2006-03-20 2007-03-20 Chimeric constructs between cancer-homing peptides and cell-penetrating peptides coupled to anticancer drugs and/or diagnostic agent/agents

Publications (1)

Publication Number Publication Date
ATE495197T1 true ATE495197T1 (de) 2011-01-15

Family

ID=38522712

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07716076T ATE495197T1 (de) 2006-03-20 2007-03-20 Chimäre konstrukte zwischen auf krebs zielenden peptiden und zellpenetrierenden peptiden gekoppelt an antikrebsmittel und/oder diagnostische mittel

Country Status (5)

Country Link
US (1) US20100279918A1 (de)
EP (1) EP1991586B1 (de)
AT (1) ATE495197T1 (de)
DE (1) DE602007011901D1 (de)
WO (1) WO2007108749A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9101671B2 (en) 2007-01-03 2015-08-11 Sanford-Burnham Medical Research Institute Methods and compositions related to clot binding compounds
EP2250278B1 (de) * 2008-02-21 2023-04-05 Burnham Institute for Medical Research Verfahren und zusammensetzungen in zusammenhang mit peptiden und proteinen mit c-terminalen elementen
EP2445536B1 (de) 2009-06-22 2016-06-08 Burnham Institute for Medical Research Verfahren und zusammensetzungen mit peptiden und proteinen mit c-terminalen elementen
WO2011020107A2 (en) * 2009-08-14 2011-02-17 Georgetown University Compositions and methods for detection and treatment of breast cancer
EP2512497A1 (de) 2009-12-18 2012-10-24 Sanford-Burnham Medical Research Institute Verfahren und zusammensetzungen im zusammenhang mit gerinnselbindenden verbndungen
CA2800730C (en) * 2010-05-30 2019-06-11 The Governing Council Of The University Of Toronto Mitochondrial penetrating peptides as carriers for antimicrobials
CN103097397B (zh) * 2010-05-30 2015-11-25 多伦多大学管理委员会 作为抗癌化合物载体的线粒体穿透肽
EP2671597A1 (de) * 2012-06-07 2013-12-11 Cepep III AB Chimäre Konstrukte zwischen gliomabzielendem Peptid und zellpenetrierenden Peptiden, gHoPe2
CN110037999B (zh) 2012-08-13 2023-01-13 洛克菲勒大学 治疗和诊断黑素瘤
CN103981147B (zh) 2013-02-08 2017-11-10 中国科学院上海生命科学研究院 一种新的制备肝实质细胞的方法
WO2014147193A1 (en) * 2013-03-20 2014-09-25 Centre National De La Recherche Scientifique (Cnrs) New cell-penetrating peptide motifs
PL3149025T3 (pl) * 2014-05-21 2019-11-29 Entrada Therapeutics Inc Peptydy penetrujące komórkę i sposoby ich wytwarzania i stosowania
US10815276B2 (en) 2014-05-21 2020-10-27 Entrada Therapeutics, Inc. Cell penetrating peptides and methods of making and using thereof
EP3185880B1 (de) 2014-08-27 2020-02-12 Ohio State Innovation Foundation Verbesserte peptidyl-calcineurin-hemmer
US10669311B2 (en) 2015-04-23 2020-06-02 Sanford Burnham Prebys Medical Discovery Institute Targeted delivery system and methods of use therefor
WO2018227112A1 (en) 2017-06-09 2018-12-13 The Trustees Of Columbia University In The City Of New York Short tat oligomers for drug delivery
WO2019104062A1 (en) 2017-11-21 2019-05-31 Rgenix, Inc. Polymorphs and uses thereof
WO2019148194A2 (en) 2018-01-29 2019-08-01 Ohio State Innovation Foundation Peptidyl inhibitors of calcineurin-nfat interaction
TW201945014A (zh) 2018-02-22 2019-12-01 美商安卓達治療股份有限公司 用於治療粒線體性神經胃腸腦病變之組合物及方法
WO2019217682A1 (en) 2018-05-09 2019-11-14 Ohio State Innovation Foundation Cyclic cell-penetrating peptides with one or more hydrophobic residues
CN112386707B (zh) * 2019-08-19 2023-08-11 辽宁医学诊疗科技研发中心有限公司 一种肿瘤靶向多肽药物偶联物及其制备方法
AU2020401286A1 (en) 2019-12-13 2022-06-23 Inspirna, Inc. Metal salts and uses thereof
EP4281034A1 (de) 2021-01-24 2023-11-29 Forrest, Michael, David Inhibitoren der atp-synthase kosmetische und therapeutische verwendungen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030077826A1 (en) * 2001-02-02 2003-04-24 Lena Edelman Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC)
US7488792B2 (en) * 2002-08-28 2009-02-10 Burnham Institute For Medical Research Collagen-binding molecules that selectively home to tumor vasculature and methods of using same
WO2004106370A1 (en) * 2003-05-28 2004-12-09 Theraptosis Sa M11l derived peptides and therapeutic use thereof
WO2004108883A2 (en) * 2003-06-10 2004-12-16 Toolgen, Inc. Transducible dna-binding proteins
EP1968643A2 (de) * 2005-12-16 2008-09-17 Diatos Zell-penetrierende peptid-konjugate zur abgabe von nukleinsäuren in eine zelle

Also Published As

Publication number Publication date
EP1991586A1 (de) 2008-11-19
WO2007108749A8 (en) 2009-08-13
WO2007108749A1 (en) 2007-09-27
DE602007011901D1 (de) 2011-02-24
EP1991586B1 (de) 2011-01-12
US20100279918A1 (en) 2010-11-04

Similar Documents

Publication Publication Date Title
ATE495197T1 (de) Chimäre konstrukte zwischen auf krebs zielenden peptiden und zellpenetrierenden peptiden gekoppelt an antikrebsmittel und/oder diagnostische mittel
PH12014501642B1 (en) Peptide vaccines for cancers expressing tumor-associated antigens
ES2850726T3 (es) Péptidos de penetración celular para suministro intracelular de moléculas
NZ601818A (en) Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of gastric cancer and other cancers
MX2009004147A (es) Vacunas de peptido para canceres que expresan polipeptidos mphosph1 o depdc1.
UA103882C2 (uk) Композиція пухлино-асоційованих пептидів та відповідна протиракова вакцина
Suk Choi et al. Cell penetrating peptides for tumor targeting
UA100127C2 (ru) Пептид cdh3 и лекарственное средство, содержащее его
Yamaguchi et al. Identification of cyclic peptides for facilitation of transcellular transport of phages across intestinal epithelium in vitro and in vivo
AR067627A1 (es) Enlazador fmoc polimerico hidrolizable. procedimiento de preparacion
US20150119340A1 (en) Fusion peptide and use thereof for cell membrane penetrating
MX2015005867A (es) Moleculas de transporte especificas de proteoglicano c4s.
Biswas et al. Applications of Peptide in Cancer Therapy
US20240092846A1 (en) Engineered cyclotides with potent broad antimicrobial activity

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties